Is a global healthcare company that provides innovative health solutions through its prescription drugs, vaccines, biotherapy and animal health products. The operation of the company is mainly managed on the basis of products, including four operating departments, namely pharmacy, animal health care, medical and health services and alliance departments.
Besides prescription drug business, Merck also includes nearly 50 kinds of veterinary products in China, covering disease prevention, treatment and control of livestock, poultry and pets, and is committed to protecting and caring for animal health and human health.
China is an important part of Merck's global growth strategy. Merck China is headquartered in Shanghai and employs more than 5,000 people. 20 13 April, the new factory of Merck East Hangzhou, covering an area of 75,000 square meters, was officially put into use, which is one of the most advanced and largest pharmaceutical production and packaging factories in China and even the Asia-Pacific region.
social responsibility
Merck firmly believes that enterprises with a high sense of social responsibility can create more business value. 1992 the national seroepidemiological survey showed that there were 65438+200 million HBV carriers in China at that time, and nearly one tenth of newborns were infected with HBV every year.
From 65438 to 0989, Merck reached a technology transfer license agreement with the government of China to provide China with the world's most advanced genetic engineering hepatitis B vaccine production technology at that time, to help China's scientific and technological personnel go to the United States for training, and to help set up hepatitis B vaccine production workshops in Beijing and Shenzhen. Today, these technologies and equipment are still operating effectively, benefiting the people of China.
The vaccination of recombinant hepatitis B vaccine has greatly improved public health in China. According to the data released by the Disease Control Bureau of the Ministry of Health of China in August of 20 1 1, during the period from 192 to 20 10/8, the number of hepatitis B virus infections in China decreased by about 80 million, and the number of children with hepatitis B virus surface antigen decreased by nearly 19.
Reference to the above content: Baidu Encyclopedia-Merck